The International Online Journal of Cancer & Therapeutics is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.


committee

Members

ThumbnailImage

Lei Wang

Postdoctoral research fellow,

2011.9-2014.6 - Ph.D, Urinary Surgery, the Second Clinical College, Wuhan University, Wuhan, China
Project Title: Mechanisms in resistance to Chemoradiotherapy of Prostate Cancer Stem Cells
2007.9-2010.7 - M.S, Oncology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Project Title: Prognostic Value of Thymidine Phosphorylase/Platelet-derived Endothelial Cell
Growth Factor and Thrombocytosis in Gastric Carcinoma
1997.9-2002.7 - B.S., Clinical Medicine, Wuhan University, Wuhan, China

  • Mechanisms in resistance to chemoradiotherapy of cancer stem cells
  • 2014 Outstanding graduate student Awards (Wuhan University)
  • 2013 National Scholarship for Doctoral Candidates (Wuhan University)
  • 2012 The Third Science and Technology Progress Awards of Xiangyang (Xiangyan Municipal People’s Government)

[1] Wang L, Huang X, Zheng X, et al. Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Clin Transl Oncol, 2014, 16(6): 567-572.
[2] Wang L, Huang X, Zheng X, et al. Enrichment of Prostate Cancer Stem-Like Cells from Human Prostate Cancer Cell Lines by Culture in Serum-Free Medium and Chemoradiotherapy. Int J Biol Sci, 2013, 9(5): 472-479.
[3] Wang L, Huang X, Chen Y, et al. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric
carcinoma. Eur J Surg Oncol, 2012, 38(7): 568-573.
[4] Huang X, Wang L, Zheng XM, Wang XH. Comparison of perioperative, functional, and
oncological outcomes between standard laparoscopic and robotic-assisted radical
prostatectomy: a systemic review and meta-analysis. Eur J Surg Oncol (manuscript number:
EJSO-D-16-00270), under review.
[5] Huang X, Wang L, Chen Y, Zheng XM, Wang XH. Poor prognosis associated with high levels of
thymidine phosphorylase and thrombocytosis in patients with renal cell carcinoma. Urologia
Internationalis. (on line)
[6] Huang X, Wang L, Wang XH, Shi HB, Zhang XJ, Yu ZY. Bipolar transurethral resection of the
prostate causes deeper coagulation depth and less bleeding than monopolar transurethral
prostatectomy. Urology, 80(5): 1116-1120, 2012.
[7] Wang L, Ning JF, Wakimoto H, Wu SL, Wu CL, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus and phosphoinositide 3-kinase/Akt pathway inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. (ready for submission)